Free Trial
OTCMKTS:CPMV

Mosaic ImmunoEngineering (CPMV) Stock Price, News & Analysis

Mosaic ImmunoEngineering logo
$0.27 -0.26 (-48.48%)
As of 03:10 PM Eastern

About Mosaic ImmunoEngineering Stock (OTCMKTS:CPMV)

Key Stats

Today's Range
$0.27
$0.27
50-Day Range
$0.49
$0.84
52-Week Range
$0.10
$1.13
Volume
223 shs
Average Volume
1,009 shs
Market Capitalization
$1.97 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Mosaic ImmunoEngineering, Inc., a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use. Its lead immunotherapy product candidate, MIE-101, a nanoparticle-based treatment derived from cowpea mosaic virus, which is non-infectious in humans and animals. The company was founded in 2020 and is based in Novato, California.

Mosaic ImmunoEngineering Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
7th Percentile Overall Score

CPMV MarketRank™: 

Mosaic ImmunoEngineering scored higher than 7% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Mosaic ImmunoEngineering.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Mosaic ImmunoEngineering is -1.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Mosaic ImmunoEngineering is -1.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Mosaic ImmunoEngineering's valuation and earnings.
  • Percentage of Shares Shorted

    0.01% of the float of Mosaic ImmunoEngineering has been sold short.
  • Short Interest Ratio / Days to Cover

    Mosaic ImmunoEngineering has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

  • Dividend Yield

    Mosaic ImmunoEngineering does not currently pay a dividend.

  • Dividend Growth

    Mosaic ImmunoEngineering does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.01% of the float of Mosaic ImmunoEngineering has been sold short.
  • Short Interest Ratio / Days to Cover

    Mosaic ImmunoEngineering has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

  • News Sentiment

    Mosaic ImmunoEngineering has a news sentiment score of 1.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • Insider Buying vs. Insider Selling

    In the past three months, Mosaic ImmunoEngineering insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    80.99% of the stock of Mosaic ImmunoEngineering is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Read more about Mosaic ImmunoEngineering's insider trading history.
Receive CPMV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mosaic ImmunoEngineering and its competitors with MarketBeat's FREE daily newsletter.

CPMV Stock News Headlines

Mosaic ImmunoEngineering, Inc. (CPMV)
Mosaic Co.
Banks aren’t ready for this altcoin—are you?
I've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. This is about being in the right place at the right time – and I believe that time is now.
See More Headlines

CPMV Stock Analysis - Frequently Asked Questions

Mosaic ImmunoEngineering's stock was trading at $0.7012 at the beginning of the year. Since then, CPMV stock has decreased by 61.2% and is now trading at $0.2720.
View the best growth stocks for 2025 here
.

Mosaic ImmunoEngineering, Inc. (OTCMKTS:CPMV) announced its earnings results on Tuesday, May, 20th. The company reported ($0.03) earnings per share (EPS) for the quarter.

Shares of CPMV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Mosaic ImmunoEngineering investors own include BioNxt Solutions (BNXTF), Defense Metals (DFMTF), C3.ai (AI), Applied Genetic Technologies (AGTC), Agile Therapeutics (AGRX), AgriFORCE Growing Systems (AGRI) and

Company Calendar

Last Earnings
5/20/2025
Today
5/28/2025
Next Earnings (Estimated)
8/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
OTCMKTS:CPMV
Employees
3
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$1.01 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
($0.81) per share
Price / Book
-0.34

Miscellaneous

Free Float
1,377,000
Market Cap
$1.97 million
Optionable
Not Optionable
Beta
0.11
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (OTCMKTS:CPMV) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners